Conference: ACoP 2026
Date: October 11 - 14, 2026
Location: Gaylord National Harbor, Oxon Hill, MD 20745
Booth: 17 & 18
Platinum Sponsor
Honoree: Samer Mouksassi, Certara
Samer Mouksassi will be recognized as a Fellow of the International Society of Pharmacometrics (FISoP) — one of the Society’s highest honors, a career-achievement award for sustained and substantial contributions to the science of pharmacometrics, to ISoP, and to the broader model-informed drug development community. New Fellows are honored during the ACoP opening ceremony.
Where to hear Certara insights and expertise
Workshops:
Room: Chesapeake H
Certara presenters: Certara Phoenix team
A hands-on session with the Certara Phoenix team.
Registration link forthcoming
Room: Chesapeake H
Certara instructors: Joshua F. Apgar and Andrew Matteson, Certara
With hundreds of FDA and EMA submissions now supported by QSP models, quantitative systems pharmacology has come of age — yet most preclinical and clinical programs still aren’t supported by QSP. This workshop unveils Certara IQ™, an environment built to scale QSP from a handful of projects to the entire pipeline. Through worked, practical examples, instructors demonstrate how to apply Certara IQ across four key decision points: new target feasibility, best-in-class properties, first-in-human dose projection, and recommended Phase 2 dose.
Registration:
$450 ACoP Attendees
$300 Students with code STUDENTACOP26
Presentations:
Certara presentation: “Mechanistic Modeling as the Translational Engine: Converting NAM Data into Predictive Human PK/PD and Safety Insights” (11:40 AM – 12:00 PM)
Certara presenter: Piet van der Graaf, Certara
Certara Chair: Samer Mouksassi, Certara (with instructors from AstraZeneca and Eli Lilly)
Certara presenter: Piet van der Graaf, Certara
Certara presentation: Certara contributes “PBPK Models to Medicines” within the session, alongside talks on PBPK in regulatory science and PBPK with AI, and a panel discussion.
Certara presenter: Amin Rostami-Hodjegan, Certara
Certara presentation: “Strengths and Limitations of MBMA as a Tool to Accelerate Drug Development in Rare Diseases” (2:25 – 2:50 PM)
Certara presenter: Matt L. Zierhut, Certara
Certara presentation: “Optimizing PROTACs in Preclinical ADME: From In Vitro Assays to Clinical Translation” (10:30 – 10:50 AM)
Certara presenter: Sibylle Neuhoff, Certara
Certara presentation: “Applications of Real-World Data to MIDD: Insights to Surmount Challenges Gained from Ongoing Research in Alzheimer’s Disease and Pediatric Populations” (3:00 – 3:20 PM)
Certara presenter: Ananth Kadambi, Real World Evidence & Modeling Solutions, Certara
Panel Discussion (4:00 – 4:30 PM) — Certara panelist: Ananth Kadambi.
Chair: Samer Mouksassi, PharmD,PhD,FCP
Presentation within session: Current clinical applications and latest trends in drug development using CUI and other forms of multi-attribute utility approaches- Non-Oncology Case Studies
Presenter: Samer Mouksassi, PharmD,PhD,FCP
Connect with Certara’s scientific and regulatory experts to explore how integrated modeling software and tech-enabled consulting can support confident decision-making across your development program, from early clinical strategy through global submission.
Schedule time with our team at ACoP to discuss your specific challenges and identify practical, model-informed solutions tailored to your program.
Secure your meeting now to ensure dedicated time with our experts onsite.
You May Also Like
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
